Key takeaways:

• Xdemvy is the first FDA-approved treatment specifically for Demodex blepharitis.
• Lotion-based formulas such as Ndemex should be adjuncts to lid hygiene or prescription therapy.

Demodex blepharitis is a common inflammatory eyelid condition with meaningful consequences for patients’ daily functioning and quality of life.

As awareness grows and diagnostic guidance evolves, clinicians are also navigating a rapidly expanding management landscape that now includes prescription antiparasitic therapy, established lid hygiene strategies and an emerging lotion-based formulation.

Management fundamentals

Historically, management of Demodex blepharitis centered on symptom control through warm compresses, eyelid hygiene, topical or oral antimicrobials, and anti-inflammatory agents. Lid hygiene — wipes, cleansers or foams — remains foundational. These approaches help remove debris, reduce inflammatory load, support ocular surface homeostasis and establish daily care routines that many patients can maintain.

However, real-world data illustrate the limits of hygiene alone for some patients. In a study from Barnett and colleagues, commonly used strategies included artificial tears, warm compresses and lid wipes, yet nearly half of patients who discontinued their regimen cited tolerability issues or lack of perceived effectiveness. Similar findings have been reported elsewhere, underscoring challenges with adherence and durability of symptom control (Ho et al.; O’Dell et al.).

Prescription therapy

A major inflection point in Demodex blepharitis management occurred with the introduction of Xdemvy (lotilaner ophthalmic solution, Tarsus Pharmaceuticals), the first FDA-approved treatment specifically indicated for Demodex blepharitis. Lotilaner inhibits parasite-specific GABA-chloride channels, leading to paralysis and death of Demodex mites. Pooled analyses of pivotal trials demonstrated significant reductions in collarettes, mite eradication and lid margin erythema compared with vehicle, with benefits sustained in extension studies up to 1 year and no long-term safety concerns identified (Gaddie et al.; Muhammad et al.; Sadri et al.; Syed; Talha et al.).

In parallel, expert guidance has begun to coalesce. The Demodex Expert Panel on Treatment and Eyelid Health published consensus recommendations addressing diagnosis, comorbidities and management principles, emphasizing collarette reduction as a primary treatment objective and advising caution with tea tree oil products regarding tolerability and potential meibomian gland effects. These developments have provided clinicians with clearer pathways for diagnosis and escalation of care (Amescua et al.; Farid et al.).

Maintenance therapy

Even with prescription therapy, Demodex blepharitis remains a chronic condition for many patients who may require ongoing maintenance strategies alongside episodic or targeted treatments. Moreover, some patients express interest in nonprescription or botanically derived options, particularly for long-term eyelid care, provided safety and tolerability can be maintained.

Tea tree oil and its derivatives have long been explored for their antimicrobial and acaricidal properties. Terpinen-4-ol, a key component of tea tree oil, has demonstrated in vitro activity against Demodex mites and broad antimicrobial effects (Cheung et al.; Rhee et al.). However, high-concentration tea tree oil formulations used in office settings are not suitable for home use, and uncertainty has persisted regarding whether lower concentrations can reliably achieve demodicidal effects without irritation (Cheung et al.; Rhee et al.; Savla et al.). These challenges have driven interest in formulation strategies that might balance efficacy with tolerability.

One such approach uses a lipid nanoparticle encapsulation system that is intended to improve delivery and tolerability of active components. The newly released Ndemex (Bruder) is one such example. This lotion-based eyelid formulation incorporates terpinen-4-ol alongside botanical ingredients commonly used to support eyelid comfort, including green tea, chamomile and sea whip extract, and has been shown to exert demodicidal activity (Hom). As a no-rinse lotion, it represents a different format from traditional wipes, foams or drops.

From a clinical perspective, such products are best considered adjunctive and not replacements for lid hygiene or prescription therapy — additional tools within a stepped or individualized management plan. For patients with ongoing irritation, recurrent collarettes or a need for long-term eyelid care, lotion-based formulations with demodicidal intent may offer a practical option to integrate alongside daily hygiene routines.

Expanding the toolbox

The heterogeneity of patient presentations and preferences underscores the value of a broad clinical toolbox. As evidence continues to evolve, clinicians will be better equipped to match the right combination of tools to each patient.

For more information:

Amy Hellem, PhD, FAAO, director of the National Keratoconus Foundation and founder of Hellem Consulting, can be reached at amyhellem@me.com. Milton M. Hom, OD, in private practice at Canyon City Eyecare in Azusa, California, can be reached at eyemage@mminternet.com.